Obesity study: Eloralintide and tirzepatide vs Tirzepatide
Official title A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
ClinicalTrials.gov ID: NCT07881458
What this study is testing
What is eloralintide and tirzepatide?
eloralintide and tirzepatide is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for obesity.
Also referred to as LY900043.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to investigate how well it works and how safe it is of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in people with obesity or overweight and type 2 diabetes.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Have type 2 diabetes
- Have a stable self-reported body weight (\<5% body weight change) for 90 days prior to screening
- Have a BMI of ≥27 kg/m2 at screening
- Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight
You likely can't join if
- Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
- Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if...
- Have type 1 diabetes
- Have taken any of the following within 90 days prior to screening
- medications with direct amylin, glucagon-like peptide-1 (GLP-1) or glucagon-dependent insulinotropic polypeptide (GIP) receptor activity, including...
- dipeptidyl peptidase 4 (DPP-4) inhibitors, and
See the full eligibility criteria
- Have type 2 diabetes
- Have a stable self-reported body weight (\<5% body weight change) for 90 days prior to screening
- Have a BMI of ≥27 kg/m2 at screening
- Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight
- Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
- Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
- Have type 1 diabetes
- Have taken any of the following within 90 days prior to screening
- medications with direct amylin, glucagon-like peptide-1 (GLP-1) or glucagon-dependent insulinotropic polypeptide (GIP) receptor activity, including compounded therapies
- dipeptidyl peptidase 4 (DPP-4) inhibitors, and
- insulin
- heart attack
- stroke
- coronary artery revascularization
- unstable angina, or
- hospitalization due to congestive heart failure
- Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
- Have taken medications or alternative remedies intended for weight loss within 90 days of screening
The study team makes the final eligibility decision.
Where it is enrolling
- Los Angeles, California, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Los Angeles, California, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.